This content is machine translated MASH and heart health The underestimated cardiovascular threat Metabolic-associated steatohepatitis (MASH) was long considered a purely hepatic problem. Today, data from large clinical trials and registries clearly show that cardiovascular disease is the most common cause of death...…
View Post 2 min This content is machine translated Wearables: screening via smartwatch? New study on atrial fibrillation in high-risk patients Wearable devices with photoplethysmography and ECG capabilities offer a non-invasive and scalable method of monitoring heart rate. A recently published randomized controlled trial provided evidence that six months of screening...…
View Post 11 min This content is machine translated Sleep apnea and cardiovascular diseases Breathless through the night 936 million people affected worldwide, a cardiovascular risk profile that complements traditional risk factors and new pharmacological treatment options: Current evidence from 2024-2026 paints a clearer picture of a link...…
View Post 6 min This content is machine translated Secondary prevention after ACS: individually optimized lipid management Trend towards early combination therapy and new strategies for lowering Lp(a) Secondary prevention after an acute coronary syndrome (ACS) is crucial for improving quality of life and reducing morbidity and mortality rates. Elevated blood lipid levels such as LDL cholesterol and...…
View Post 6 min This content is machine translated Acute pulmonary embolism: new AHA/ACC guideline Practical recommendations for risk-stratified triage In February 2026, the American Heart Association (AHA) and the American College of Cardiology (ACC) published a new guideline on the assessment and treatment of acute pulmonary embolism in cooperation...…
View Post 13 min This content is machine translated Why lipoprotein(a) is the biggest therapeutic vacuum in cardiology Lp(a): The underestimated risk factor before the turning point One in five people worldwide has a genetically elevated lipoprotein(a) – and knows nothing about it. Unlike LDL cholesterol, this independent, causally significant risk factor cannot be significantly influenced by...…
View Post 14 min This content is machine translated Heart failure and type 2 diabetes Oral semaglutide and cardiac decompensation in type 2 diabetes The secondary analysis of the SOUL trial from JAMA Internal Medicine 2026 proves for the first time: Oral semaglutide significantly reduces heart failure events in patients with pre-existing HFpEF –...…
View Post 12 min This content is machine translated Current evidence, risk classes and new counseling options Hormonal contraception and cardiovascular risk Over 247 million women worldwide use hormonal contraception – the majority with combined oral contraceptives (COCs). This prevalence is accompanied by an ongoing medical responsibility: venous thromboembolism, ischemic strokes and...…
View Post 13 min This content is machine translated MACE risk, heart failure incidence and all-cause mortality Metabolic syndrome as a cardiovascular risk factor Current data from 2025/2026 show: 1.54 billion adults worldwide are affected – and the risk of serious cardiovascular events increases in proportion to the number of components. New evidence on...…
View Post 9 min This content is machine translated Cardiology Minimally invasive – the quiet triumph of modern heart surgery The median sternotomy was the standard approach for cardiac surgery for many decades. With the advent of minimally invasive procedures, the guiding question of cardiac surgery shifted: away from maximum...… CME-Test
View Post 10 min This content is machine translated Patients with leg swelling DVT and other common DDs with peripheral edema Swelling of the lower extremities is common, especially in older adults. Due to the complex interrelationships, the clarification of such findings in general practice is a challenge. The differential diagnostic...…
